Windtree Therapeutics Earnings Call Transcripts
Fiscal Year 2024
-
Istaroxime, a dual-mechanism agent for cardiogenic shock, has shown consistent efficacy and safety in phase II studies, improving blood pressure, cardiac output, and renal function without increasing heart rate or arrhythmias. Ongoing SEISMIC studies and a focused phase III program aim to address a significant unmet need in a growing market.
-
Istaroxime showed rapid, significant improvements in blood pressure, cardiac output, and renal function in phase II studies for cardiogenic shock, with a favorable safety profile and strong physician interest. The company is prioritizing this indication for its faster regulatory path and high unmet need, while advancing acute heart failure and next-generation assets through partnerships.
-
Istaroxime showed rapid, significant improvements in blood pressure, cardiac output, and renal function in phase II cardiogenic shock studies, with a favorable safety profile and strong physician interest. The company is advancing to studies in more severe patients and preparing for phase 3 trials, while actively pursuing partnerships and funding.